MARKET

BIOR

BIOR

BIORA THERAPEUTICS INC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.010
+0.240
+31.17%
Pre Market: 0.9949 -0.0151 -1.50% 07:52 08/11 EDT
OPEN
0.8800
PREV CLOSE
0.7700
HIGH
1.150
LOW
0.8369
VOLUME
47.43K
TURNOVER
--
52 WEEK HIGH
6.20
52 WEEK LOW
0.5600
MARKET CAP
186.04M
P/E (TTM)
-0.6283
1D
5D
1M
3M
1Y
5Y
Biora rallies 30%, highest since November on data for drug delivery device
Biora Therapeutics (NASDAQ:BIOR), a biotech focused on o...
Seekingalpha · 18h ago
BRIEF-Biora Therapeutics Announces Successful Completion Of Device Performance Study In Ulcerative Colitis Patients For Its Targeted Therapeutics Platform
BRIEF-Biora Therapeutics Announces Successful Completion Of Device Performance Study In Ulcerative Colitis Patients For Its Targeted Therapeutics Platform
Reuters · 22h ago
Biora Therapeutics Announces Successful Completion of Device Performance Study in Ulcerative Colitis Patients for its Targeted Therapeutics Platform
All Devices Successfully Detected Colon Entry in Patients with Active Ulcerative ColitisSAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced topline resu...
GlobeNewswire · 22h ago
Biora Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update
SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced that it will report second quarter ended June 30, 2022 financial results on Monday, August 15, 2022 ...
GlobeNewswire · 2d ago
BRIEF-Biora Therapeutics Announces Five Abstracts Accepted At American College Of Gastroenterology Annual Scientific Meeting 2022
BRIEF-Biora Therapeutics Announces Five Abstracts Accepted At American College Of Gastroenterology Annual Scientific Meeting 2022
Reuters · 08/03 13:15
Biora Therapeutics to Participate in Upcoming BTIG Investment Conference
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced that the company’s management team will be participating in one-on-one meetings at the upcoming BTIG...
GlobeNewswire · 07/26 13:00
--HC Wainwright Adjusts Price Target on Biora Therapeutics to $6 From $4, Reiterates Buy Rating
MT Newswires · 07/15 05:24
BRIEF-Biora Therapeutics Shares Preclinical Data On Oral Delivery Of Biologics At Controlled Release Society 2022
BRIEF-Biora Therapeutics Shares Preclinical Data On Oral Delivery Of Biologics At Controlled Release Society 2022
Reuters · 07/14 13:45
More
No Data
Learn about the latest financial forecast of BIOR. Analyze the recent business situations of BIORA THERAPEUTICS INC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BIOR stock price target is 5.00 with a high estimate of 6.00 and a low estimate of 4.000.
High6.00
Average5.00
Low4.000
Current 1.010
EPS
Actual
Estimate
-0.98-0.74-0.49-0.25
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 59
Institutional Holdings: 51.03M
% Owned: 27.71%
Shares Outstanding: 184.20M
TypeInstitutionsShares
Increased
14
4.61M
New
12
879.48K
Decreased
10
1.29M
Sold Out
15
1.62M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+2.49%
Healthcare Equipment & Supplies
+2.35%
Key Executives
Non-Executive Chairman/Independent Director
Jeffrey Alter
Chief Executive Officer/Director
Aditya Mohanty
Chief Financial Officer
Eric D'esparbes
Senior Vice President/General Counsel/Secretary
Clarke Neumann
Senior Vice President
Paul Shabram
Independent Director
Jeffrey Ferrell
Independent Director
Jill Howe
Independent Director
Brian Kotzin
Independent Director
Lynne Powell
Independent Director
Surbhi Sarna
No Data
No Data
About BIOR
Biora Therapeutics, Inc., formerly Progenity, Inc., is a biotechnology company focused on developing oral biotherapeutics. It delivers therapeutics in two areas: targeted delivery of therapeutics to the site of disease in the gastrointestinal tract and systemic delivery of biotherapeutics. Its research and development pipeline consists of Drug Delivery System (DDS), PGN-600, PGN-001, Oral Biotherapeutics Delivery System (OBDS), PGN-OB1 and PGN-OB2. PGN-600 is liquid formulation of tofacitinib delivered with the DDS for the treatment of ulcerative colitis. PGN-001 is an orally-delivered variant of adalimumab for the treatment of ulcerative colitis. PGN-OB1 is a combination product of a variant of adalimumab and the OBDS for the treatment of inflammatory conditions. PGN-OB2 is a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type two diabetes. The OBDS platform is designed to enable delivery of liquid drug, reducing the need for reformulation.

Webull offers kinds of Biora Therapeutics Inc stock information, including NASDAQ:BIOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIOR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BIOR stock methods without spending real money on the virtual paper trading platform.